| 2.635 0.135 (5.4%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.58 |
1-year : | 8.95 |
| Resists | First : | 5.64 |
Second : | 7.67 |
| Pivot price | 3.33 |
|||
| Supports | First : | 2.36 |
Second : | 1.96 |
| MAs | MA(5) : | 3 |
MA(20) : | 3.57 |
| MA(100) : | 7.26 |
MA(250) : | 13.9 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7  |
| %K %D | K(14,3) : | 2.4 |
D(3) : | 5.7 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 44.79 | Low : | 2.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BPTH ] has closed above bottom band by 20.1%. Bollinger Bands are 16.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.75 - 2.77 | 2.77 - 2.78 |
| Low: | 2.33 - 2.34 | 2.34 - 2.36 |
| Close: | 2.61 - 2.63 | 2.63 - 2.66 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Fri, 19 Apr 2024
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study - Yahoo Finance
Thu, 18 Apr 2024
Why Bio-Path Stock Is Soaring - Bio-Path Hldgs (NASDAQ:BPTH) - Benzinga
Thu, 18 Apr 2024
Bio-Path shares rally after clinical trial progress of BP1002 (NASDAQ:BPTH) - Seeking Alpha
Mon, 15 Apr 2024
BioPath Hikes on International Patents - Baystreet.ca
Tue, 02 Apr 2024
Bio-Path Holdings Announces 2024 Clinical and Operational Progress - TipRanks.com - TipRanks
Tue, 26 Mar 2024
Is Bio Path Holdings Inc (BPTH) Stock Worth a Buy Tuesday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 67 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -33.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.2 % |
| Return on Equity (ttm) | -220.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -20.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | 3.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|